Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
The Best Stocks to Invest $500 in Right Now
02:45am, Thursday, 04'th Jun 2026
The market is underestimating these companies' long-term prospects.
British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy
07:04pm, Wednesday, 03'rd Jun 2026
The UK cost-effectiveness watchdog on Thursday recommended AbbVie's "guided missile" cancer therapy, Elahere, for patients with a hard-to-treat form of ovarian cancer.
AbbVie Delivers 400% Returns Beating The S&P 500 by 139%
12:06pm, Wednesday, 03'rd Jun 2026
Ten years ago, AbbVie (NYSE:ABBV | ABBV Price Prediction) was a one-drug story.
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine
11:06am, Wednesday, 03'rd Jun 2026
ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:00am, Wednesday, 03'rd Jun 2026
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
This Is What a $1 Million Dividend Portfolio Pays After Taxes
07:45am, Wednesday, 03'rd Jun 2026
At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic
02:30pm, Tuesday, 02'nd Jun 2026
AbbVie's shareholders can sleep easy.
The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains
09:45am, Tuesday, 02'nd Jun 2026
AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
08:00am, Tuesday, 02'nd Jun 2026
NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026.
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
04:00am, Tuesday, 02'nd Jun 2026
AQUIPTA (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the prophylaxis of
3 Dividend Stocks to Buy and Hold Forever
03:00am, Tuesday, 02'nd Jun 2026
These aren't the most exciting businesses, but they have a lot to offer to long-term investors.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
02:19pm, Monday, 01'st Jun 2026
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.
AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript
02:14pm, Friday, 29'th May 2026
AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript
AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?
12:31pm, Friday, 29'th May 2026
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?
Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial Fixed-
